Trial recruiting · ClinicalTrials.gov · Sep 25
A 52-week Study of Remibrutinib in IgE-mediated Food Allergy (opens in a new tab)
Phase 3 · Ages 12 to 65 · Sites in 12 US states
The purpose of this Phase III study is to evaluate the clinical efficacy and safety of remibrutinib in participants with peanut, or cow's milk ("milk", cooked and uncooked) or hen's egg ("egg", cooked and uncooked) immunoglobulin E (IgE)- mediated allergy in…
ResearchTesting and diagnosisRecipes and cooking